Avid Bioservices Inc (CDMO)

[cjgaddy]

CHI/I-O 2-21-17 Talk switched from JH to Dr.Michael.Gray, Senior Research Scientist at Peregrine. I actually noticed this chg. several days ago, didn’t think much of it, and had it queued to update iBox the next time I update.

Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & Immuno-Oncology”, SanFran
“Models & Approaches to Bring Combination Therapies to the Clinic”
Part of the 24th Intl. Molecular Medicine Tri-Conference
http://www.triconference.com/Pre-Clinical-Oncology-Models
CHI = Cambridge Healthtech Institute http://www.healthtech.com
Track: TUMOR MODELS FOR CANCER IMMUNOTHERAPY
2-21-17 11:15-11:45am: Dr. Michael Gray (Sr.Res.Scientist), Peregrine Pharmaceuticals - “Case Study: Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
SUMMARY:
Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of checkpoint antibodies in preclinical tumor models.

= = = = = = = =Recall:
9-27-16 AACR-CRI/Dr. Michael Gray: Preclin. Triple-Combo Bavi+PD1+LAG3 TNBC data in TNBC (80% Compl. Regression, Stat-Sig. Incr. in Key Tumor Fighting Immune Cells)
http://tinyurl.com/zy9yv78
“...the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of multiple checkpoint targeting agents including anti-PD-1 & anti-LAG3 therapies in a model of triple negative breast cancer (TNBC). Data showed that 8 of the 10 (80%) animals receiving the preclinical bavituximab equivalent (ch1N11) combined with anti-PD-1 and anti-LAG3 therapies ("Triple Combination") experienced complete tumor regressions, whereas there were no animals (0/10) in the anti-PD-1 & anti-LAG3 combination treatment arm that had a complete regression. Addl. data demonstrated that the Triple Combination featuring ch1N11 led to a 99% reduction in total tumor volume at the interim analysis point (Day 25) across all animals as compared to the control arm. In addition, the Triple Combination showed a statistically significant increase in tumor growth inhibition (TGI) as compared to the anti-PD-1 & anti-LAG3 combination treatment (99% vs. 62%; p < 0.05). Peregrine's Michael J. Gray, PhD, the study's lead scientist, presented the study findings at the 2nd CRI-CIMT-EATI-AACR Intl. Cancer Immunotherapy Conf. Sept. 25-28, 2016, in NYC.”
**DR. MICHAEL GRAY: https://www.linkedin.com/in/michael-gray-18447328 “Principal Scientist, joined Peregrine 12-2014, prev=OSI, Educ=MDA"